Phase 3 Studies Treating Children and Adult Patients with Mild to Moderate Atopic Dermatitis with Crisaborole Ointment, a Novel, Nonsteroidal, Topical Anti-inflammatory, Phosphodiesterase 4 Inhibitor

Mapping Intimacies ◽

10.1542/peds.141.1_meetingabstract.275 ◽

2018 ◽

Author(s):

Amy S. Paller ◽

Wynnis L. Tom ◽

Mark G. Lebwohl ◽

Mark Boguniewicz ◽

Lawrence F. Eichenfield ◽

...

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Anti Inflammatory ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

A Novel Nonsteroidal, Topical Anti-inflammatory, Phosphodiesterase 4 Inhibitor, Crisaborole Ointment, Reduced Pruritus and Signs of Atopic Dermatitis in 2 Phase 3 Studies in Children and Adults

10.1542/peds.141.1_meetingabstract.251 ◽

2018 ◽

Author(s):

Adelaide A. Hebert ◽

Lawrence F. Eichenfield ◽

Mark G. Lebwohl ◽

Amy S. Paller ◽

Eric L. Simpson ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Anti Inflammatory ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Crisaborole topical ointment, 2%: A novel, nonsteroidal, topical antiinflammatory, phosphodiesterase 4 inhibitor: Results from two phase 3 studies treating children and adult patients with mild to moderate atopic dermatitis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.02.337 ◽

2016 ◽

Vol 74 (5) ◽

pp. AB86 ◽

Cited By ~ 1

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Phase 3 ◽

Two Phase ◽

Phosphodiesterase 4 ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterase-4 inhibitor, in dogs with atopic dermatitis

Veterinary Record ◽

10.1136/vr.145.7.191 ◽

1999 ◽

Vol 145 (7) ◽

pp. 191-194 ◽

Cited By ~ 25

Author(s):

L. Ferrer ◽

J. Alberola ◽

M. Queralt ◽

P. Brazis ◽

R. Rabanal ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phosphodiesterase 4 ◽

Anti Inflammatory ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Faculty Opinions recommendation of Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718458515.793501282 ◽

2014 ◽

Author(s):

Hidehisa Saeki

Keyword(s):

Clinical Trial ◽

Atopic Dermatitis ◽

Adult Patients ◽

Multicenter Clinical Trial ◽

Japanese Adult ◽

Safety And Efficacy ◽

Phosphodiesterase 4 ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

286 Phase 3 studies in atopic dermatitis with the novel, nonsteroidal topical phosphodiesterase 4 inhibitor, crisaborole

Journal of Investigative Dermatology ◽

10.1016/j.jid.2016.02.316 ◽

2016 ◽

Vol 136 (5) ◽

pp. S50 ◽

Cited By ~ 2

Author(s):

A.S. Paller ◽

W.L. Tom ◽

R.S. Call ◽

L. Eichenfield ◽

D. Forsha ◽

...

Keyword(s):

Atopic Dermatitis ◽

The Novel ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Difamilast ointment, a selective phosphodiesterase 4 inhibitor, in paediatric patients with atopic dermatitis: A phase 3 randomised double‐blind, vehicle‐controlled trial

British Journal of Dermatology ◽

10.1111/bjd.20655 ◽

2021 ◽

Author(s):

H. Saeki ◽

N. Baba ◽

K. Ito ◽

D. Yokota ◽

H. Tsubouchi

Keyword(s):

Atopic Dermatitis ◽

Controlled Trial ◽

Phase 3 ◽

Double Blind ◽

Phosphodiesterase 4 ◽

Paediatric Patients ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: Results of a randomized, vehicle-controlled, multicenter clinical trial

The Journal of Dermatology ◽

10.1111/1346-8138.12534 ◽

2014 ◽

Vol 41 (7) ◽

pp. 577-585 ◽

Cited By ~ 42

Author(s):

Masutaka Furue ◽

Yasumi Kitahara ◽

Hideto Akama ◽

Seiichiro Hojo ◽

Nobukazu Hayashi ◽

...

Keyword(s):

Clinical Trial ◽

Atopic Dermatitis ◽

Adult Patients ◽

Multicenter Clinical Trial ◽

Japanese Adult ◽

Safety And Efficacy ◽

Phosphodiesterase 4 ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Long-term Safety of Crisaborole, a Novel, Nonsteroidal, Topical, Anti-inflammatory, Phosphodiesterase 4 Inhibitor in Children and Adults with Mild to Moderate Atopic Dermatitis

10.1542/peds.141.1_meetingabstract.271 ◽

2018 ◽

Author(s):

Lawrence F. Eichenfield ◽

Robert S. Call ◽

Douglass W. Forsha ◽

Joseph Fowler ◽

Adelaide A. Hebert ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phosphodiesterase 4 ◽

Anti Inflammatory ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

SAT0392 Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of A Phase 3, Randomized, Controlled Trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2014-eular.4419 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 736.1-736 ◽

Cited By ~ 1

Author(s):

F. Zhang ◽

T. Tencer ◽

S. Li

Keyword(s):

Randomized Controlled Trial ◽

Psoriatic Arthritis ◽

Controlled Trial ◽

Work Productivity ◽

Phase 3 ◽

Productivity Improvement ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

TAS-203, an oral phosphodiesterase 4 inhibitor, exerts anti-inflammatory activities in a rat airway inflammation model

European Journal of Pharmacology ◽

10.1016/j.ejphar.2019.01.068 ◽

2019 ◽

Vol 849 ◽

pp. 22-29 ◽

Cited By ~ 2

Author(s):

Shunsuke Demizu ◽

Naomasa Asaka ◽

Hiroyuki Kawahara ◽

Eiji Sasaki

Keyword(s):

Airway Inflammation ◽

Phosphodiesterase 4 ◽

Inflammation Model ◽

Anti Inflammatory ◽

Phosphodiesterase 4 Inhibitor

Download Full-text